Platform Discovery & Validation
Oncology
DiscoveryActive
Key Facts
About Kahimmune Therapeutics
Kahimmune Therapeutics is an early-stage biotech developing cancer immunotherapies based on targets from the dark genome, a largely unexplored area of non-coding DNA. Its platform aims to discover and validate novel tumor antigens to create potent and specific vaccines and immunotherapies with the potential for improved safety and efficacy. As a private, pre-revenue company, it is likely in a foundational or pre-clinical research phase, building its scientific platform and initial pipeline. The company's success hinges on validating its novel approach, securing sustained funding, and navigating the highly competitive oncology immunotherapy landscape.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |